

Workshop Radiopharmaceuticals, Bern, 12. September 2018

What is the focus of clinical review?



Wild Damian, Mitglied Fachkommission für Radiopharmazeutika FKRP, Abteilungsleiter Nuklearmedizin Universitätsspital Basel

Swissmedic • Swiss Agency for Therapeutic Products • Hallerstrasse 7 • 3012 Berne • Switzerland • www.swissmedic.ch

Submission of clinical information


- Package insert (Fachinformation),
Swissmedic does not require a patient information sheet
- Clinical documentation (Modul 5. Swissmedic information sheet)

Inhaltsverzeichnis

1	Zielsetzung.....	2
2	Geltungsbereich	2
3	Mitgeltende Dokumente	2
4	Dokumentation	2
4.5	Klinische Dokumentation (Modul 5)	7
4.5.1	Radiodiagnostika:	8
4.5.2	Radiotherapeutika:	8

All details can be found in the Swissmedic information sheet, documentation for authorization of radiopharmaceuticals.

Focus of clinical review

- I. Clinical efficacy**
 - II. Unwanted effects**
 - III. Contraindications**
 - IV. Warnings and Precautions**
 - V. Interactions**
 - VI. Overdose**
 - VII. Indication**
 - VIII. Activity dose/Administration**
 - IX. Procedures (imaging and therapy)**
 - X. Pharmacokinetics/pharmacodynamics**
- benefit
- risk
- 
- A diagram consisting of two large curly braces on the right side of the list. The top brace groups items I through III and is labeled "benefit". The bottom brace groups items IV through X and is labeled "risk".

Focus of clinical review

Benefit-risk assessment – FDA’s benefit-risk framework

<i>Benefit-Risk Integrated Assessment</i>		
<i>Benefit-Risk Dimensions</i>		
Dimension	Evidence and Uncertainties	Conclusions and Reasons
Analysis of Condition		
Current Treatment Options		
Benefit		
Risk and Risk Management		

Focus of clinical review

I. Clinical efficacy - benefit

Always justification of the design of the clinical trial

Focus of clinical review

IV. Warnings and Precautions

The packet insert must include specific instructions for

- **patients of child-bearing age;**
pregnancy test is mandatory in these patients especially before receiving therapeutic activities of radiopharmaceuticals

Dosage Card (Version 5.7.2016)

Multiple of Baseline Activity

Weight kg	Class A	Class B	Class C	Weight kg	Class A	Class B	Class C
3	1	1	1	32	3.77	7.29	14.00
4	1.12	1.14	1.33	34	3.88	7.72	15.00
6	1.47	1.71	2.00	36	4.00	8.00	16.00
8	1.71	2.14	3.00	38	4.18	8.43	17.00
10	1.94	2.71	3.67	40	4.29	8.86	18.00
12	2.18	3.14	4.67	42	4.41	9.14	19.00
14	2.35	3.57	5.67	44	4.53	9.57	20.00
16	2.53	4.00	6.33	46	4.65	10.00	21.00
18	2.71	4.43	7.33	48	4.77	10.29	22.00
20	2.88	4.86	8.33	50	4.88	10.71	23.00
22	3.06	5.29	9.33	52-54	5.00	11.29	24.67
24	3.18	5.71	10.00	56-58	5.24	12.00	26.67
26	3.35	6.14	11.00	60-62	5.47	12.71	28.67
28	3.47	6.43	12.00	64-66	5.65	13.43	31.00
30	3.65	6.86	13.00	68	5.77	14.00	32.33

$$A[MBq]_{\text{Administered}} = \text{BaselineActivity} \times \text{Multiple}$$

Administration

Provide specific instructions

and breast feeding

indications, etc.

instructions

Administration

Always justification of the proposed activity dose
- only as much as necessary -

Focus of clinical review

IX. Procedures (imaging and therapy)

The packet insert must include specific instructions for

- **scanning the patient;**
e.g. specific preparation before scanning, recommended scanning time, instructions for reading the scans etc.

Focus of clinical review

Objections in the clinical review - Period 2016 until now

- I. Clinical efficacy**
- II. Unwanted effects**
- III. Contraindications**
- IV. Warnings and Precautions**
- V. Interactions**
- VI. Overdose**
- VII. Indication** 1 x correction of indication
- VIII. Activity dose/Administration** 3 x missing justification of dosage
- IX. Procedures (imaging and therapy)** 4 x adding information about scan protocol/scan reading instructions
- X. Pharmacokinetics/pharmacodynamics**

Questions?